Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 135.21 USD 0.16%
Market Cap: 21.4B USD
Have any thoughts about
Illumina Inc?
Write Note

Illumina Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Illumina Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Illumina Inc
NASDAQ:ILMN
Gross Profit
$2.8B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
9%
Thermo Fisher Scientific Inc
NYSE:TMO
Gross Profit
$17.3B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Gross Profit
$12.6B
CAGR 3-Years
-9%
CAGR 5-Years
8%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Gross Profit
$2.2B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Gross Profit
$3.5B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
6%
IQVIA Holdings Inc
NYSE:IQV
Gross Profit
$5.4B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
14%
No Stocks Found

Illumina Inc
Glance View

Market Cap
21.5B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.

ILMN Intrinsic Value
144.84 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Illumina Inc's Gross Profit?
Gross Profit
2.8B USD

Based on the financial report for Sep 29, 2024, Illumina Inc's Gross Profit amounts to 2.8B USD.

What is Illumina Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
9%

Over the last year, the Gross Profit growth was 2%. The average annual Gross Profit growth rates for Illumina Inc have been -2% over the past three years , 3% over the past five years , and 9% over the past ten years .

Back to Top